AbbVie Inc. R&D Expenses

R&D Expenses of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including R&D Expenses growth rates and interactive chart. Research and development (R&D) expenses are associated with the research and development of a company's goods or services. A company generally incurs R&D expenses in the process of finding and creating new products or services. It is an operating expense and can be deducted from a company's income taxes.


Highlights and Quick Summary

  • R&D Expenses for the quarter ending December 30, 2019 was $1.54 Billion (a -32.52% decrease compared to previous quarter)
  • Year-over-year quarterly R&D Expenses increased by 19.63%
  • Annual R&D Expenses for 2019 was $6.41 Billion (a -37.97% decrease from previous year)
  • Annual R&D Expenses for 2018 was $10.3 Billion (a 106.29% increase from previous year)
  • Annual R&D Expenses for 2017 was $5.01 Billion (a 14.18% increase from previous year)
  • Twelve month R&D Expenses ending December 30, 2019 was $6.41 Billion (a -43.6% decrease compared to previous quarter)
  • Twelve month trailing R&D Expenses decreased by -38.24% year-over-year
Trailing R&D Expenses for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
$6.41 Billion $11.4 Billion $10.3 Billion $10.4 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical R&D Expenses of AbbVie Inc.

Most recent R&D Expensesof ABBV including historical data for past 10 years.

Interactive Chart of R&D Expenses of AbbVie Inc.

AbbVie Inc. R&D Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $1,542.0 $2,285.0 $1,291.0 $1,289.0 $6,407.0
2018 $6,495.0 $1,268.0 $1,322.0 $1,244.0 $10,329.0
2017 $1,408.0 $1,228.0 $1,229.0 $1,142.0 $5,007.0
2016 $1,209.0 $1,106.0 $1,124.0 $946.0 $4,385.0
2015 $1,075.0 $1,418.0 $981.0 $811.0 $4,285.0
2014 $879.0 $812.0 $834.0 $772.0 $3,297.0
2013 $798.0 $714.0 $709.0 $634.0 $2,855.0
2012 $681.0 $813.0 $642.0 $642.0 $2,778.0
2011 $2,602.91 $0.0 $0.0 $587.1 $2,618.0
2010 $2,495.0
2009 $1,707.44

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.